Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $48.41 million. The enterprise value is $29.81 million.
Important Dates
The next estimated earnings date is Friday, March 28, 2025, after market close.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 27.51 million shares outstanding. The number of shares has increased by 71.33% in one year.
| Current Share Class | 27.51M |
| Shares Outstanding | 27.51M |
| Shares Change (YoY) | +71.33% |
| Shares Change (QoQ) | +2.22% |
| Owned by Insiders (%) | 21.16% |
| Owned by Institutions (%) | 16.10% |
| Float | 17.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.76 |
| P/TBV Ratio | 2.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.47 |
| Quick Ratio | 3.30 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -118.50% and return on invested capital (ROIC) is -75.29%.
| Return on Equity (ROE) | -118.50% |
| Return on Assets (ROA) | -60.54% |
| Return on Invested Capital (ROIC) | -75.29% |
| Return on Capital Employed (ROCE) | -124.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $38,341 in taxes.
| Income Tax | 38,341 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.14% in the last 52 weeks. The beta is 0.23, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -41.14% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 31.71 |
| Average Volume (20 Days) | 83,491 |
Short Selling Information
The latest short interest is 335,267, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 335,267 |
| Short Previous Month | 378,863 |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.89% |
| Short Ratio (days to cover) | 3.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.06M |
| Pretax Income | -18.18M |
| Net Income | -21.89M |
| EBITDA | -23.05M |
| EBIT | -23.06M |
| Earnings Per Share (EPS) | -$0.83 |
Full Income StatementBalance Sheet
The company has $19.69 million in cash and $1.09 million in debt, giving a net cash position of $18.60 million or $0.68 per share.
| Cash & Cash Equivalents | 19.69M |
| Total Debt | 1.09M |
| Net Cash | 18.60M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 17.55M |
| Book Value Per Share | 0.64 |
| Working Capital | 16.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.80 million and capital expenditures -$683,706, giving a free cash flow of -$16.48 million.
| Operating Cash Flow | -15.80M |
| Capital Expenditures | -683,706 |
| Free Cash Flow | -16.48M |
| FCF Per Share | -$0.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |